PMID- 31156625
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20200813
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After 
      Allogeneic Hematopoietic Stem Cell Transplantation.
PG  - 1034
LID - 10.3389/fimmu.2019.01034 [doi]
LID - 1034
AB  - Immune exhaustion contributes to treatment failure after allogeneic hematopoietic 
      stem cell transplantation (HSCT) for hematological malignancies. Immune 
      checkpoint blockade, including programmed cell death protein-1 (PD-1) blockade, 
      is a promising strategy to improve the antitumor effect of allogeneic HSCT with 
      high rates of response reported in patients treated for disease relapse. However, 
      severe and sometimes fatal Graft- vs.-Host-Disease (GvHD) has been reported as a 
      complication. Little is known about the dynamics of PD-1 expression on immune 
      effector cells after allogeneic HSCT. In the present study, we analyzed PD-1 
      expression on T cell subpopulations isolated from 105 allogeneic HSCT recipients. 
      Our analysis revealed a significant increase in proportions of PD-1-expressing 
      CD4 and CD8 T cells early after allogeneic HSCT followed by a progressive 
      normalization of PD-1 expression at CD8 but not CD4 T cell surface. Analysis of 
      co-expression of two other exhaustion markers, 2B4 and CD160, revealed a 
      preferential expansion of PD-1-single positive cells. Moreover, the analysis of 
      granzyme B and perforin expression in PD-1+ and PD-1- CD8 T cells from HSCT 
      recipients did not reveal any impairment in cytotoxic molecules production by 
      PD-1-expressing CD8 T cells. Analyzing the association between clinical factors 
      and the expression of PD-1 on T cells, we identified the use of in vivo and/or ex 
      vivo T-cell depletion as the factor most strongly associated with elevated PD-1 
      levels on T cells. Our results extend our knowledge of the regulation of PD-1 
      expression at T cell surface after allogeneic HSCT, a crucial information for the 
      optimization of post-transplantation PD-1 blocking therapies.
FAU - Simonetta, Federico
AU  - Simonetta F
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Pradier, Amandine
AU  - Pradier A
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Bosshard, Carine
AU  - Bosshard C
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Masouridi-Levrat, Stavroula
AU  - Masouridi-Levrat S
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Dantin, Carole
AU  - Dantin C
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Koutsi, Aikaterini
AU  - Koutsi A
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Tirefort, Yordanka
AU  - Tirefort Y
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Roosnek, Eddy
AU  - Roosnek E
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Chalandon, Yves
AU  - Chalandon Y
AD  - Division of Hematology, Department of Oncology, Geneva University Hospitals and 
      Faculty of Medicine, University of Geneva, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190516
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (B7-H1 Antigen)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - B7-H1 Antigen/antagonists & inhibitors
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Female
MH  - Graft vs Host Disease/immunology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/*analysis/antagonists & inhibitors
MH  - Prospective Studies
MH  - Transplantation, Homologous
MH  - Young Adult
PMC - PMC6531929
OTO - NOTNLM
OT  - HSCT
OT  - PD-1
OT  - checkpoint inhibitors
OT  - exhaustion
OT  - transplantation
EDAT- 2019/06/04 06:00
MHDA- 2020/08/14 06:00
PMCR- 2019/01/01
CRDT- 2019/06/04 06:00
PHST- 2019/01/20 00:00 [received]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2019/06/04 06:00 [entrez]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01034 [doi]
PST - epublish
SO  - Front Immunol. 2019 May 16;10:1034. doi: 10.3389/fimmu.2019.01034. eCollection 
      2019.